CN Patent

CN119212709A — 抑郁的治疗

Assigned to Antecip Bioventures II LLC · Expires 2024-12-27 · 1y expired

What this patent protects

本公开涉及在某些患者群体中施用以下的组合：1)约100‑110mg、约104‑106mg或约105mg盐酸安非他酮或摩尔当量的安非他酮的游离碱形式或另一种盐形式；以及2)约40‑50mg、约44‑46mg或约45mg氢溴酸右美沙芬或摩尔当量的右美沙芬的游离碱形式或另一种盐形式，用于治疗疼痛或神经障碍诸如抑郁。

USPTO Abstract

本公开涉及在某些患者群体中施用以下的组合：1)约100‑110mg、约104‑106mg或约105mg盐酸安非他酮或摩尔当量的安非他酮的游离碱形式或另一种盐形式；以及2)约40‑50mg、约44‑46mg或约45mg氢溴酸右美沙芬或摩尔当量的右美沙芬的游离碱形式或另一种盐形式，用于治疗疼痛或神经障碍诸如抑郁。

Drugs covered by this patent

Patent Metadata

Patent number: CN119212709A
Jurisdiction: CN
Classification: —
Expires: 2024-12-27
Drug substance claim: No
Drug product claim: No
Assignee: Antecip Bioventures II LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.